Javid Moslehi Archives
Clinical investigation society lauds Vanderbilt scientists
Mar. 12, 2020—Five faculty members of Vanderbilt University School of Medicine are among 80 physician-scientists who will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:
Study identifies targeted therapy’s cardiac risks
Sep. 25, 2019—After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
AHA statement supports vascular cardio-oncology
Feb. 21, 2019—The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.
Immunotherapies linked to specific heart complications
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Cancer immunotherapy drugs linked with more serious heart effects
Mar. 12, 2018—Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.
My Southern Health: The ABCDEs of caring for the heart during cancer treatment—and beyond
Feb. 28, 2017—People who have dealt with cancer may also need to take special care of their hearts. Here’s how.
Study details rare heart risk of certain cancer therapies
Nov. 3, 2016—Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of...
Emerging field of cardio-oncology seeks better tools
Oct. 27, 2016—Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism.
Prostate cancer survivors’ risk of heart disease studied
Feb. 4, 2016—The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression.
Cancer therapies’ impact on heart, kidneys explored
Sep. 24, 2015—Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.
Program focuses on heart health of cancer patients
Oct. 2, 2014—The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States.
